Clinical Trials Logo

Fat; Liver clinical trials

View clinical trials related to Fat; Liver.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03145350 Completed - NAFLD Clinical Trials

The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism

Start date: December 2016
Phase: N/A
Study type: Interventional

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world. It is currently unclear why fat starts to accumulate in the liver, although both the amount and type of food consumed have been implicated. The majority of studies that have investigated the effects of dietary fat or sugar on liver fat have fed volunteers excess calories, which are known to increase liver fat. The effect of specific dietary components, when consumed as part of a diet not containing excess calories, on liver fat accumulation remains unclear.

NCT ID: NCT03043235 Completed - Insulin Sensitivity Clinical Trials

Race Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity

Start date: January 8, 2014
Phase:
Study type: Observational

This research study will examine how ethnic/racial background, body composition (%body fat), and the location of body fat affect the ability of the hormone insulin to promote uptake of blood sugar in persons who are 19 to 45 years of age. When insulin is ineffective in promoting blood sugar uptake, this condition is termed "insulin resistance." Insulin resistance plays a major role in the development of chronic metabolic diseases (such as type 2 diabetes, cardiovascular disease, and cancer), many of which differ with race. Previous studies suggest that insulin resistance is higher in African-Americans (AA) vs. European-Americans (EA). However, results from these studies remain unclear due to different testing measures used for insulin resistance as well as differences in body fat between individuals. Results from this research study may help explain why insulin resistance differs with genetic background and may guide development of personalized treatment strategies with implications for several chronic metabolic diseases (e.g., type 2 diabetes, cardiovascular disease, and cancer).